Compare Danaher Corporation (DHR) vs ING Groep NV (ING) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs ING Groep NV — how do they compare? Danaher Corporation trades at $218.41 (market cap $152.87B), while ING Groep NV trades at $33.31 (market cap $93.76B). The key difference: Danaher Corporation is the larger of the two by market cap, and ING Groep NV pays the higher dividend (3.95%). Which is the better fit depends on your goals — on Pluang, investors hold Danaher Corporation for 69 Days and ING Groep NV for 93 Days on average.
| DHR | ING | |
|---|---|---|
Market Cap | $152.87B | $93.76B |
Volume | 5,228,698 | 4,620,220 |
Sector | Health | Financials |
52-Week High | $242.05 | $37.27 |
52-Week Low | $161.91 | $23.66 |
Typical Hold Time | 69 Days | 93 Days |
Enterprise Value | $175.08B | $236.48B |
Dividend Yield | 0.74% | 3.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $218.49, up 1.36% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. The stock shows strong profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst consensus is strongly bullish with a $230.31 price target, supported by institutional buying activity and a recent dividend announcement.
The outlook for DHR is positive, driven by earnings momentum and institutional confidence, but risks include elevated valuation multiples and competitive pressures in the healthcare sector. Investors should weigh the strong analyst support against potential margin compression and macroeconomic headwinds affecting capital spending.
ING stock trades at $33.92, down 2.81% today, with a bearish technical outlook despite recent earnings beats. The company shows strong profitability with 28.34% net income margin and 13.49% ROE, supported by management's raised ROE target above 16% for 2027. Recent news highlights strategic focus on organic growth and bolt-on acquisitions while maintaining capital discipline.
While analyst consensus remains strongly bullish with 65% buy ratings, negative cash flow trends and regulatory scrutiny in Australia present near-term risks. The stock's attractive valuation at 12.86 P/E offers potential upside if the company can execute on its growth strategy and improve cash generation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About ING Groep NV
The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Read more on ING →
